| abstract |
Provided herein are compounds, including enantiomerically pure forms thereof, having glucagon receptor antagonist or inverse agonist activity, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof. Further treating a pharmaceutical composition comprising it and a disease or condition in need of one or more glucagon receptor antagonists, including type I and type II diabetes, insulin resistance, and hyperglycemia, Provided herein are methods for preventing, delaying the time to onset, or reducing the risk of its occurrence or progression. Further provided herein are methods for making or manufacturing compounds disclosed herein, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof. The |